Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study

Neurobiology of Aging

Volumn 31, Issue 5, 2010, Pages 758-764

  Sluimer, Jasper D ^a   Bouwman, Femke H ^a   Vrenken, Hugo ^a   Blankenstein, Marinus A ^a   Barkhof, Frederik ^a   van der Flier, Wiesje M ^a   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Beta amyloid; CSF; Longitudinal; Mild cognitive impairment; MMSE; MRI; P tau; Tau; Whole brain atrophy rate

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ATROPHY; BIOLOGICAL MARKERS; BRAIN; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 77950538544     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.06.016     Document Type: Article

References (35)

1. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 10(October):605-613.
2. Bouwman F.H., Schoonenboom S.N.M., van Der Flier W.M., Van Elk E.J., Kok A., Barkhof F., Blankenstein M.A., Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging 2007, 28:1070-1074.
3. Bouwman F.H., van Der Flier W.M., Schoonenboom N.S., Van Elk E.J., Kok A., Rijmen F., Blankenstein M.A., Scheltens P. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007 2007, 69(September (10)):1006-1011.
4. Bouwman F.H., van Der Flier W.M., Schoonenboom N.S., Van Elk E.J., Kok A., Scheltens P., Blankenstein M.A. Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. Clin. Chem. 2006, 52(August (8)):1604-1606.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 1991, 82(4):239-259.
6. Chan D., Fox N.C., Jenkins R., Scahill R.I., Crum W.R., Rossor M.N. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology 2001, 57(November (10)):1756-1763.
7. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., Rusinek H., Li J., Tsui W., Saint Louis L.A., Clark C.M., Tarshish C., Li Y., Lair L., Javier E., Rich K., Lesbre P., Mosconi L., Reisberg B., Sadowski M., DeBernadis J.F., Kerkman D.J., Hampel H., Wahlund L.O., Davies P. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 2006, 27(March (3)):394-401. (Epub August 26, 2005).
8. Erten-Lyons D., Howieson D., Moore M.M., Quinn J., Sexton G., Silbert L., Kaye J. Brain volume loss in MCI predicts dementia. Neurology 2006, 66(January (2)):233-235.
9. Folstein M.F., Folstein S.E., Mchugh P.R. " Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12(November (3)):189-198.
10. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
11. Fox N.C., Scahill R.I., Crum W.R., Rossor M.N. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999, 52(May (8)):1687-1689.
12. Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., Cummings J.L., de L.M., Feldman H., Ganguli M., Hampel H., Scheltens P., Tierney M.C., Whitehouse P., Winblad B. Mild cognitive impairment. Lancet 2006, 367(April (9518)):1262-1270.
13. Hampel H., Burger K., Pruessner J.C., Zinkowski R., DeBernardis J., Kerkman D., Leinsinger G., Evans A.C., Davies P., Moller H.J., Teipel S.J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2005, 62(May (5)):770-773.
14. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Moller H.J., Blennow K., Buerger K. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 2004, 9:705-710.
15. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5(March (3)):228-234.
16. Hartley S.W., Scher A.I., Korf E.S.C., White L.R., Launer L.J. Analysis and validation of automated skull stripping tools: a validation study based on 296 MR images from the Honolulu Asia aging study. Neuroimage 2006, 30:1179-1186.
17. Herukka S.K., Helisalmi S., Hallikainen M., Tervo S., Soininen H., Pirttila T. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging 2007, 28(April (4)):507-514. (Epub March 20, 2006).
18. Jack C.R., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., Boeve B.F., Ivnik R.J., Smith G.E., Cha R.H., Tangalos E.G., Petersen R.C. Comparison of different MRI brain atrophy, rate measures with clinical disease progression in AD. Neurology 2004, 62:591-600.
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(July (7)):939-944.
20. MRC CFAS Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001, 357(January (9251)):169-175.
21. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51(December (6)):1546-1554.
22. O'Brien J.T., Paling S., Barber R., Williams E.D., Ballard C., McKeith I.G., Gholkar A., Crum W.R., Rossor M.N., Fox N.C. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001, 56(May (10)):1386-1388.
23. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56(May (9)):1133-1142.
24. Ridha B.H., Barnes J., Bartlett J.W., Godbolt A., Pepple T., Rossor M.N., Fox N.C. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006, 5:828-834.
25. Schonknecht P., Pantel J., Hartmann T., Werle E., Volkmann M., Essig M., Amann M., Zanabili N., Bardenheuer H., Hunt A., Schroder J. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res. 2003, 120(October (3)):231-238.
26. Schoonenboom N.S., van Der Flier W.M., Blankenstein M.A., Bouwman F.H., Van Kamp G.J., Barkhof F., Scheltens P. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol. Aging 2007, (January).
27. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61(August (4)):487-492.
28. Sluimer, J.D., van Der Flier, W.M., Karas, G., Fox, N., Scheltens, P., Barkhof, F., Vrenken, H., 2008. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 248 (August) 590-598. (Epub June 23, 2008).
29. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E., Johansen-Berg H., Bannister P.R., De L.M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De S.N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(Suppl. 1):S208-S219.
30. Smith S.M., Zhang Y., Jenkinson M., Chen J., Matthews P.M., Federico A., De S.N. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002, 17(September (1)):479-489.
31. van Straaten E.C., Scheltens P., Knol D.L., van Buchem M.A., van Dijk E.J., Hofman P.A., Karas G., Kjartansson O., de Leeuw F.E., Prins N.D., Schmidt R., Visser M.C., Weinstein H.C., Barkhof F. Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study. Stroke 2003, 34(August (8)):1907-1912. (Epub July 10, 2003).
32. Visser P.J., Kester A., Jolles J., Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006, 67(October (7)):1201-1207.
33. Wahlund L.O., Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 2003, 339(March (2)):99-102.
34. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., Scheltens P., Tariska P., Winblad B. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 2007, 14(January (1)):e1-e26.
35. Wiltfang J., Lewczuk P., Riederer P., Grunblatt E., Hock C., Scheltens P., Hampel H., Vanderstichele H., Iqbal K., Galasko D., Lannfelt L., Otto M., Esselmann H., Henkel A.W., Kornhuber J., Blennow K. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J. Biol. Psychiatry 2005, 6(2):69-84.